title: Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia.
abstract: OBJECTIVE
  Intensive as compared to mild statin therapy has been proven to be superior in improving cardiovascular outcome, whereas the effects of intensive statin therapy on inflammation and lipoprotein biomarkers are not well defined.
  
  
  METHODS
  This study assigned essential hypertensive patients with dyslipidemia to 6 months administration of mild (1 mg/day, n = 34) or intensive pitavastatin therapy (4 mg/day, n = 29), and various lipid and inflammation biomarkers were measured at baseline, and 3 and 6 months after the start of treatment.
  
  
  RESULTS
  Both pitavastatin doses were well tolerated, and there were no serious treatment-related adverse events. After 6 months, significant improvements in total cholesterol, triglycerides, low-density lipoprotein (LDL-) cholesterol, LDL/high-density lipoprotein cholesterol (LDL/HDL), apolipoproteins B, C-II, and E, apolipoprotein-B/apolipoprotein-A-I (Apo B/Apo A-I), and malondialdehyde (MDA-) LDL were observed in both groups. Compared with the mild pitavastatin group, the intensive pitavastatin therapy showed significantly greater decreases in C reactive protein (F = 3.76, p<0.05), total cholesterol (F = 10.65), LDL-cholesterol (F = 23.37), LDL/HDL (F = 12.34), apolipoproteins B (F = 19.07) and E (F = 6.49), Apo B/Apo A-I (F = 13.26), and MDA-LDL (F = 5.76) (p<0.01, respectively).
  
  
  CONCLUSIONS
  Intensive pitavastatin therapy may have a more favorable effect not only in decreasing LDL-cholesterol but also in pleiotropic benefits in terms of improvement of apolipoproteins, inflammation, or oxidation.
authors.affiliation: Division of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Yamasaki
authors.affiliation: Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Iwashima
authors.affiliation: Faculty of Medicine, University of Tsukuba, Tsukuba City, Ibaragi, Japan.
authors.forename: Subrina
authors.initials: S
authors.lastname: Jesmin
authors.affiliation: Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ohta
authors.affiliation: Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kusunoki
authors.affiliation: Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Hayashi
authors.affiliation: Department of General Internal Medicine 3, Kawasaki Medical School, Okayama City, Okayama, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Horio
authors.affiliation: Division of Hypertension and Nephrology, National Cerebral and Cardiovascular Center, Suita City, Osaka, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Kawano
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D007249:Inflammation / Q000097:blood*; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; C108475:pitavastatin